29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS Download PDF Category: 2024By Alexis BERNARD31 May 2024 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Pin itShare on Pinterest Author: Alexis BERNARD Post navigationPreviousPrevious post:AB Science webcast of May 30, 2024NextNext post:Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSRelated PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
